Joint pain innovators invited to apply for Chugai and IBM challenge
Chugai and IBM are seeking companies with disruptive technologies or developing innovations in the understanding of joint pain and maintaining joint integrity.
Chugai has been involved over many years in therapeutic areas achieving success with medications that tackle joint damage in both immunology and haematology. The company aims to create objectivity and accuracy in interpreting joint integrity and joint pain thereby increasing the understanding of what is happening in a patient’s joint and thereby improve diagnosis and treatment pathways for patients.
Chugai Pharma Europe would welcome ‘pitches’ from partners that could aid in searching for a disruptive innovation that objectively identifies and/or monitors the course of pain within a joint which could help optimise patients’ treatment. The disruptive technology (although not limited to) could help in the following ways:
- Support achieving the goal of accurate real time management of joint health by speeding up the process of reporting joint pain and integrity between physicians and patients.
- Understand the cause of joint pain and/or how understanding joint pain can optimise a patient’s journey.
- Ability to predict potential disease flare accurately and quickly within a joint.
Applications are invited if you meet one or more of the following criteria:
- Applicants with directly relevant joint health experience.
- Applicants with other healthcare experience.
- Applicants with regulated industry experience, who are used to documenting decisions for regulatory purposes (examples include aerospace, transport).
Technology
Applications are invited if you meet one or more of the following criteria:
- Non-commercial technologies previously used for research purposes.
- Explainable AI/ML.
- Technology Readiness Level 4.
Regulatory
Applications are invited if you meet one or more of the following criteria:
- The organisation must be incorporated as a legal registered entity to receive support.
- CE-marked or able to become CE-marked.
- Able and willing to undergo country or region-specific Health Technology Appraisals or requirements.
Chugai and IBM will select a small number of stand-out teams to progress forward and work on the challenge.
This Challenge offers opportunities for all applicants:
- General awareness, promotion and branding for all applicants.
- The opportunity to showcase your solution to key stakeholders within Chugai Pharma Europe with the support of IBM and Whitespace.
- Opportunities for all applicants to join IBM’s Partner Ecosystem.
- Potential partnership with IBM and Chugai to access new markets and accelerate product and/or service development.
The winner of the challenge will have the opportunity to accelerate the development of their solution in collaboration with Chugai and IBM, with business opportunities and access to their technology and experts.
Applications close on 28th February 2022, with the selection process taking place between March and April.